Clinical trials: Brentuximab
Hodgkin Disease
A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity
An early phase II, single arm, two stage study, to investigate the level of activity, duration of response and tolerability of brentuximab vedotin (SGN-35), as a single agent, utilising a response adapted approach, in older…
- Trial name
- BREVITY (NCT02567851)
- Testing
- Brentuximab Vedotin
- Where
- 12 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- University of Birmingham
Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
- Trial name
- NCT00866047
- Testing
- brentuximab vedotin
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 58 people
- Sponsor
- Seagen Inc.
Recurrent Adult Hodgkin Lymphoma
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of temsirolimus when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has returned or has not responded to treatment.
- Trial name
- NCT01902160
- Testing
- Brentuximab Vedotin, Laboratory Biomarker Analysis, Temsirolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin's Disease
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,
The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and…
- Trial name
- CheckMate 812 (NCT03138499)
- Testing
- Nivolumab, Brentuximab vedotin
- Where
- 22 sites in United States, Japan and 1 more
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Hodgkin Lymphoma
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
This study aims to evaluate the efficacy of brentuximab vedotin + AVD combination (doxorubicine, vinblastine, dacarbazine) in patients with Hodgkin lymphoma stage I / II with an unfavorable diagnosis, assessed by the negativity…
- Trial name
- BREACH (NCT02292979)
- Testing
- Doxorubicin, Bleomycin, Vinblastine
- Where
- 65 sites in Belgium, Croatia and 3 more
- Volunteers
- 170 people
- Sponsor
- The Lymphoma Academic Research Organisation
Classical Hodgkin Lymphoma
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
The aim of the trial is to improve disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV)…
- Trial name
- NCT03652441
- Testing
- Brentuximab Vedotin
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University of Cologne
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
- Trial name
- NCT03907488
- Testing
- Biospecimen Collection, Brentuximab Vedotin, Computed Tomography
- Where
- 728 sites in United States, Canada and 1 more
- Volunteers
- 994 people
- Sponsor
- National Cancer Institute (NCI)
Lymphatic Diseases
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
This is a single-arm, open-label, multicenter, phase 2 clinical trial aimed at evaluating the efficacy and safety of the combination of bendamustine and brentuximab vedotin as a first salvage therapy in patients with relapsed or…
- Trial name
- FIL-BBV (NCT02499627)
- Testing
- Brentuximab Vedotin, Bendamustine
- Where
- 5 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly
The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-Cell Lymphoma.
- Trial name
- NCT01671813
- Testing
- brentuximab vedotin
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Relapsed or Refractory Hodgkin's Lymphoma
Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin
The goal of this is study is focusing on assessment of patient-reported outcomes in terms of quality of life (QoL) and symptom profile as well on evaluation of clinical efficacy and safety of BV in patients with…
- Trial name
- NCT03440788
- Testing
- Brentuximab Vedotin
- Where
- 9 sites in Russia
- Volunteers
- 70 people
- Sponsor
- Multinational Center for Quality of Life Research, Russia
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
This phase II trial studies how well brentuximab vedotin before autologous (taken from an individual's own cells) stem cell transplant works in treating patients with Hodgkin lymphoma.
- Trial name
- NCT01393717
- Testing
- brentuximab vedotin
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- City of Hope Medical Center
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
This study is investigating the combination of Brentuximab vedotin and lenalidomide in the treatment of relapsed/refractory peripheral T cell lymphoma or cutaneous T cell lymphoma or Hodgkin lymphoma.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Lymphoma
- Trial name
- EpiBrentlen (NCT03302728)
- Testing
- Lenalidomide 15mg, Brentuximab Vedotin 1.8 mg/Kg
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
This is a multicenter, observational real world study with prospective follow up that will evaluate the treatment approach in patients with relapsed/refractory cHL who undergo ASCT in Argentina.
- Conditions
- Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
- Trial name
- NCT04776265
- Testing
- Evaluation of therapeutical approach after ASCT
- Where
- 15 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Hodgkin Lymphoma
A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
The main aim is to check how effective BV is for treating adults with HL. Study medication will be prescribed according to the clinic's standard practice. Participants will visit the study clinic 5 times, once every 12 weeks.
- Trial name
- BV-MAZOVIA (NCT05100056)
- Testing
- No Intervention
- Where
- 13 sites in Poland
- Volunteers
- 70 people
- Sponsor
- Takeda
Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell…
- Conditions
- Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma
- Trial name
- ALCANZA (NCT01578499)
- Testing
- Brentuximab Vedotin, Methotrexate, Bexarotene
- Where
- 41 sites in United States, Australia and 10 more
- Volunteers
- 131 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Anaplastic Large Cell Lymphoma
BV-CHP Real-life and Biological Evidences in Patients With sALCL
Systemic Anaplastic Large Cell Lymphomas (sALCL) are rare lymphomas for which the cooperation in the collection of biological and clinical data is necessary to improve knowledge on the disease.
- Trial name
- FIL_BREAL (NCT07467317)
- Where
- 19 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Hodgkin Disease
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with…
- Trial name
- CheckMate 744 (NCT02927769)
- Testing
- Nivolumab, brentuximab vedotin, bendamustine
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
Diffuse Large B-cell-lymphoma
CD30 Imaging in Diffuse Large B-cell Lymphoma
The antibody drug conjugate (ADC) brentuximab vedotin (BV), targeting CD30, is currently registered for the treatment of previously untreated stage III-IV Hodgkin lymphoma (HL), relapsed Hodgkin lymphoma, relapsed systemic…
- Trial name
- NCT06186986
- Testing
- Brentuximab vedotin
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
CD30-positive Lymphoma, CD30-positive Solid Tumor
Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
This is an open label phase I trial designed to evaluate the maximum tolerated dose, dose-limiting toxicities, pharmacokinetics, and activity of the combination of alsertib (MLN8237) and brentuximab vedotin in patients with…
- Trial name
- AD3LE (NCT02780011)
- Testing
- Brentuximab Vedotin, Alsertib
- Where
- United States
- Sponsor
- Eric Bernicker, MD
Hodgkin Disease
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen…
- Trial name
- NCT02979522
- Testing
- Brentuximab vedotin, Doxorubicin, Vinblastine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 59 people
- Sponsor
- Takeda